Q2 2025 BioLife Solutions Inc Earnings Call Transcript
Key Points
- BioLife Solutions Inc (BLFS) reported a 29% year-over-year increase in total revenue for Q2 2025, driven by a 28% increase in cell processing revenue.
- The company raised its full-year revenue guidance, reflecting confidence in continued growth, particularly in the cell processing segment.
- BioLife Solutions Inc (BLFS) has over $100 million in cash and marketable securities, positioning it well to invest in strategic priorities.
- The company's biopreservation media product line remains strong, representing approximately 85% of Q2 cell processing revenue.
- BioLife Solutions Inc (BLFS) has a significant market share in late-stage clinical development, with its products embedded in 16 approved therapies and used in over 250 commercially sponsored CGT trials in the US.
- GAAP gross margin for Q2 2025 decreased to 62% from 64% in Q2 2024, and adjusted gross margin also declined.
- The company reported a GAAP operating loss of $16.6 million for Q2 2025, primarily due to a $15.5 million noncash IPR&D expense related to the PanTHERA acquisition.
- BioLife Solutions Inc (BLFS) experienced a decrease in cash and marketable securities from $107.6 million as of March 31, 2025, to $100.2 million as of June 30, 2025.
- The company's GAAP net loss for Q2 2025 was $15.8 million, significantly higher than the $5.6 million loss in the prior year.
- There is ongoing uncertainty in the broader CGT industry due to factors like tariffs, NIH budget pressures, and FDA leadership changes, which could impact future performance.
Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q2 2025 Shareholder and Analyst Conference Call. (Operator Instructions) This conference is being recorded. I'd now like to turn the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead, Mr.
Thank you, operator. Good afternoon, everyone, and thank you for joining the BioLife Solutions 2025 second quarter earnings conference call. On the call with me today is Roderick de Greef, CEO and Chairman of the Board. We will cover business highlights and financial performance for the quarter and provide an update for our increased 2025 revenue guidance.
Earlier today, we issued a press release announcing our financial results and operational highlights for the second quarter of 2025, which is available at biolifesolutions.com. As a reminder, during this call, we will make forward-looking statements.
These statements are subject to risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
